Cargando…
Multi-omics tumor profiling technologies to develop precision medicine in multiple myeloma
Multiple myeloma (MM), the second most common hematologic cancer, is caused by accumulation of aberrant plasma cells in the bone marrow. Its molecular causes are not fully understood and its great heterogeneity among patients complicates therapeutic decision-making. In the past decades, development...
Autores principales: | Ovejero, Sara, Moreaux, Jerome |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Open Exploration
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400753/ https://www.ncbi.nlm.nih.gov/pubmed/36046090 http://dx.doi.org/10.37349/etat.2021.00034 |
Ejemplares similares
-
Multi-omics profiling: the way toward precision medicine in metabolic
diseases
por: Hu, Cheng, et al.
Publicado: (2021) -
The Need for Multi-Omics Biomarker Signatures in Precision Medicine
por: Olivier, Michael, et al.
Publicado: (2019) -
Precision Medicine and Melanoma: Multi-Omics Approaches to Monitoring the Immunotherapy Response
por: Valenti, Fabio, et al.
Publicado: (2021) -
Multi-omics approach to precision medicine for immune-mediated diseases
por: Ota, Mineto, et al.
Publicado: (2021) -
Multi-Omics Integrative Analysis of Lung Adenocarcinoma: An in silico Profiling for Precise Medicine
por: Ruan, Xinjia, et al.
Publicado: (2022)